$ERAS investors filed a claim against Erasca for overstating ERAS-0015’s advantages while concealing risks tied to comparisons with Revolution Medicines’ RMC-6236.
After Erasca disclosed ERAS-0015 safety data and limits on comparisons to other drug candidates, $ERAS fell 48.3% on April 28, 2026.
$ERAS investors can join this case to be notified about potential recovery.
Between January 14, 2025 and April 26, 2026, Erasca stated that ERAS-0015 could be a leading treatment for RAS-mutant solid tumors.
Management highlighted stronger lab results, higher binding activity, better early performance, and a promising overall profile compared with RMC-6236.
However, investors believed Erasca’s comparisons to RMC-6236 involved risks that were not clearly disclosed. The company did not disclose that its comparisons were based on lab and early data rather than direct clinical head-to-head studies, and that these comparisons were later challenged in claims from Revolution Medicines.
According to these claims, Erasca overstated ERAS-0015’s advantages, while its comparisons with RMC-6236 were not fully supported by the available data and carried additional legal risk.
On April 27, 2026, Revolution Medicines stated that ERAS-0015 infringed a patent, misused trade secrets, and used misleading comparisons to RMC-6236.
$ERAS fell 10.9%, closing at $19.15. Later that day, additional updates included early Phase 1 data, one patient death, and clarification that comparisons to RMC-6236 were based on limited indirect analyses.
By April 28, 2026, shares had dropped to $9.90, representing a total decline of 53.9%.
Based on these events, $ERAS investors filed a case against Erasca, stating that the company:
Investors argue Erasca misled the market about ERAS-0015’s competitive position and development risks, causing losses when the truth emerged.